Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
NEW YORK, May 2, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC: GNBT) today announced that Mark Fletcher, CEO, will present at RetailInvestorConferences.com.
DATE: May 5th, 2011
TIME: 11:00 AM EDT
LINK: www.retailinvestorconferences.com>Click the red "register/ watch event now" button.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live in real-time, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expressi